USARx offers the following ways to purchase this medication. Choose the Best option for you!
Yes100% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$95 – $998
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your vimpat prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about lacosamide. Some of the dosage forms listed on this page may not apply to the brand name Vimpat.In Summary
Common side effects of Vimpat include: blurred vision, diplopia, dizziness, fatigue, headache, nausea, nystagmus disorder, tremor, vomiting, and ataxia. Other side effects include: abnormal gait, asthenia, memory impairment, and vertigo. See below for a comprehensive list of adverse effects.For the Consumer
Applies to lacosamide: oral solution, oral tablet
Other dosage forms:
Along with its needed effects, lacosamide (the active ingredient contained in Vimpat) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking lacosamide:
Incidence not known
Some side effects of lacosamide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
For Healthcare Professionals
Applies to lacosamide: intravenous solution, oral solution, oral tabletGeneral
The most commonly reported adverse reactions have included diplopia, headache, dizziness, and nausea.Nervous system
Dizziness was reported in 25% of patients randomized to the recommended doses (200 to 400 mg/day) of this drug compared with 8% of placebo patients in studies in adult patients with partial-onset seizures taking 1 to 3 concomitant AEDs. It was the event most frequently leading to discontinuation (3%). Ataxia was reported by 6% of patients randomized to the recommended doses (200 to 400 mg/day) compared to 2% in placebo patients. Dizziness and ataxia were also observed in pediatric clinical trials.
Very common (10% or more): Dizziness (up to 60%), headache (up to 13%), ataxia (up to 15%)
Common (1% to 10%): Somnolence, tremor, balance disorder, nystagmus, memory impairment, coordination abnormal, cognitive disorder, somnolence, tremor, dysarthria, disturbance in attention, paresthesia
Frequency not reported: Oral hypoesthesia, pyrexia
Postmarketing reports: Hypoesthesia, cerebellar syndrome, new or worsening seizuresGastrointestinal
Very common (10% or more): Nausea (up to 24%), vomiting (up to 16%)
Common (1% to 10%): Diarrhea, constipation, flatulence, dyspepsia, dry mouthOcular
Very common (10% or more): Diplopia (up to 16%), blurred vision (up to 16%)Hypersensitivity
Uncommon (0.1% to 1%): Hypersensitivity
Frequency not reported: Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, or DRESS)Other
Very common (10% or more): Fatigue (up to 15%)
Common (1% to 10%): Asthenia, vertigo, gait disturbance
Frequency not reported: Tinnitus, fallLocal
Common (1% to 10%): Injection site pain or discomfort
Uncommon (0.1% to 1%): Irritation, erythemaPsychiatric
Common (1% to 10%): Depression, confusional state, insomnia
Uncommon (0.1% to 1%): Aggression, agitation, euphoric mood, suicide attempt, suicidal ideation, hallucination
Frequency not reported: Irritability, feeling drunk
Postmarketing reports: Psychotic disorderDermatologic
Common (1% to 10%): Pruritus, rash
Uncommon (0.1% to 1%): Angioedema, urticaria
Frequency not reported: Neutropenia, anemia
Postmarketing reports: Stevens-Johnson syndrome, toxic epidermal necrolysisCardiovascular
During clinical trials in adult patients with partial-onset seizures, asymptomatic first-degree atrioventricular (AV) block was observed in 0.4% (4/944) of patients randomized to this drug and 0% (0/364) of placebo patients. One case of profound bradycardia was observed in a patient during a 15-minute 150 mg IV infusion.
In short-term trials in adult patients with diabetic neuropathy, atrial fibrillation occurred in 0.5% of patients (placebo=0%). Syncope occurred in 1.2% of patients (placebo=0%).
A clinical pharmacology study in healthy subjects (n=247) did not shown any QTc interval prolongation or dose-related or clinically important effects on QRS duration. This drug did produce a dose-related increase in mean PR interval; the maximum mean PR interval increase corresponded with Tmax. The placebo-subtracted maximum increase in PR interval was 7.3 ms for the 400 mg/day group and 11.9 ms for the 800 mg/day group. In clinical trials, the placebo-subtracted mean maximum increase in PR interval for a 400 mg/day dose was 3.1 ms in patients with partial-onset seizures and 9.4 ms for patients with diabetic neuropathy.
Very common (10% or more): Chest pain (up to 12%)
Common (1% to 10%): Syncope
Uncommon (0.1% to 1%): Atrioventricular block, bradycardia, atrial fibrillation, atrial flutter
Frequency not reported: Palpitations
Postmarketing reports: Cardiac arrhythmias including bradycardia, AV block, and ventricular tachyarrhythmia, which have rarely resulted in asystole, cardiac arrest, and deathMusculoskeletal
Common (1% to 10%): Muscle spasms
Frequency not reported: Connective tissue disordersHematologic
Frequency not reported: Neutropenia, anemia
Postmarketing reports: AgranulocytosisHepatic
Uncommon (0.1% to 1%): Liver function test abnormal
Frequency not reported: Hepatitis
March 31, 2021
March 29, 2021
March 27, 2021
January 25, 2021
February 23, 2021
February 9, 2021
Rite Aid, Wal-Mart, Walgreens, CVS, Duene Reade, Target, K-mart, and all national and regional chains in the United States accept the savings card.
If they are in the participating network in the U.S., they legally have to accept and process the card for our patient assistance program. If they need help in processing the card, have them call the support phone number or email us directly.
Any coupon can be applied to any prescription medication at a participating pharmacy and receive a discount. Prescription prices are subject to change by location and pharmaceutical manufacturers.
Yes, both generic and brand prescription medications from pharmaceutical manufacturers are covered by the coupon. Remember, any coupon can be applied to any prescription medication at a participating pharmacy counter and receive a discount with maximum savings.